异动解读｜巨子生物盘中上涨5.45%，交联重组胶原蛋白植入剂获批提振市场信心

行情直击06-24

6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。

消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。

多家券商对此给予积极评价，中金维持"跑赢行业"评级，目标价40港元；东方证券维持"买入"评级，目标价43.07港元，预计该产品将助力公司构建械三、械二及护肤品全品类矩阵，覆盖医疗美容全场景。当前个人用品行业整体承压，巨子生物逆势走强。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1195069610?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-06-24 10:47","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1195069610","market":"hk","top_or_hot":-1,"title":"异动解读｜巨子生物盘中上涨5.45%，交联重组胶原蛋白植入剂获批提振市场信心","media":"行情直击","content":"<p><p>6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。</p><p>消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。</p><p>多家券商对此给予积极评价，中金维持\"跑赢行业\"评级，目标价40港元；东方证券维持\"买入\"评级，目标价43.07港元，预计该产品将助力公司构建械三、械二及护肤品全品类矩阵，覆盖医疗美容全场景。当前个人用品行业整体承压，巨子生物逆势走强。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜巨子生物盘中上涨5.45%，交联重组胶原蛋白植入剂获批提振市场信心</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜巨子生物盘中上涨5.45%，交联重组胶原蛋白植入剂获批提振市场信心\n</h2>\n\n<h4 class=\"meta\">\n\n2026-06-24 10:47 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。多家券商对此给予积极评价，中金维持\"跑赢行业\"评级，目标价40...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02367","symbol_name":"巨子生物","start_time":0,"source_url":"","article_id":"1195069610","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1195069610","pubTimestamp":1782269238,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。当前个人用品行业整体承压，巨子生物逆势走强。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02367":"巨子生物"},"translate_title":"Interpretation of the change | Juzi Biotech rose 5.45% in the intraday session, and the approval of cross-linked recombinant collagen implant boosted market confidence","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02367":1},"content_text":"6月24日，巨子生物盘中上涨5.45%，报26.32港元，成交额7305.06万港元。消息面上，公司全资附属公司陕西巨子生物技术有限公司的交联重组胶原蛋白植入剂近日正式获得中国医疗器械注册证。该产品为全球首款颈纹适应症的交联重组III型全长序列胶原蛋白填充剂，采用物理交联工艺形成稳定三维网状凝胶，用于纠正颈部中重度横纹，差异化优势突出。多家券商对此给予积极评价，中金维持\"跑赢行业\"评级，目标价40港元；东方证券维持\"买入\"评级，目标价43.07港元，预计该产品将助力公司构建械三、械二及护肤品全品类矩阵，覆盖医疗美容全场景。当前个人用品行业整体承压，巨子生物逆势走强。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1195069610","isCrawlerRequest":true}